TICKERNERD
Menu
RNAHealthcare · Biotechnology

RNA Stock Forecast: Atrium Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$8.27

The 5 Wall Street analysts covering Atrium Therapeutics, Inc. hold a median 12-month price target of $25 — +202.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$141.5M
Ticker Nerd rank
5/ 100
Median analyst target
$25
Analysts covering
5
Revenue$3.0M
Operating income−$22.6M
Net income−$20.2M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

RNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atrium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
5/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
74
Size
67
Issuance
13
Value
10
Accruals
8
Growth
8
Quality
5
Momentum
4
Volatility
3

Revisions (74): Analysts have, on balance, been raising their forecasts.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNA, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $15Median $25High $25

The green dot is the last close — the median target sits +202.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Oct 2026HC Wainwright & Co.MaintainsBuy$25 → $20
22 Oct 2026Roth CapitalInitiatesBuy$15
14 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
14 Aug 2026HC Wainwright & Co.ReiteratesBuy—
6 Aug 2026HC Wainwright & Co.InitiatesBuy$25
6 Aug 2026HC Wainwright & Co.InitiatesBuy—
18 June 2026Cantor FitzgeraldInitiatesOverweight—
18 June 2026Cantor FitzgeraldInitiatesOverweight$25
15 May 2026Leerink PartnersInitiatesOutperform—
11 Mar 2026Wells FargoInitiatesOverweight—
11 Nov 2025Chardan CapitalMaintainsNeutral—
29 Oct 2025TD CowenDowngradeHold—
28 Oct 2025Chardan CapitalDowngradeNeutral—
28 Oct 2025RBC CapitalDowngradeSector Perform—
27 Oct 2025BernsteinDowngradeMarket Perform—
27 Oct 2025CitigroupDowngradeNeutral—
27 Oct 2025HC Wainwright & Co.DowngradeNeutral—
27 Oct 2025Leerink PartnersDowngradeMarket Perform—
27 Oct 2025NeedhamDowngradeHold—
27 Oct 2025Raymond JamesDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RNA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

RNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Atrium Therapeutics, Inc. (RNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 88% of US stocks

Price / sales
3.9×

Cheaper than 30% of US stocks

Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
1.8×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
−21.9%

Higher than 11% of US stocks

Earnings growth (YoY)
740.5%

Higher than 96% of US stocks

Gross margin
—
Operating margin
−752.9%

Higher than 6% of US stocks

Net margin
−184.1%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−37.0%

Higher than 25% of US stocks

Return on assets
−27.5%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Atrium Therapeutics, Inc. (RNA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Atrium Therapeutics, Inc. has a market value of $141.5M and an enterprise value of −$120.8M.

  • Revenue in the twelve months to 30 June 2026: $35.8M. The latest quarter shrank 21.9% year on year.

  • Net income over the same four quarters: −$93.2M, a −260.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$56.5M.

  • Shares outstanding: 17.1M.

  • Trailing P/E: −2.9×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Atrium Therapeutics, Inc. employs 511 people — $70K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

RNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNAAtrium Therapeutics, Inc.$141.5M5
WHWKWhitehawk Therapeutics, Inc.$184.7M71
ZNTLZentalis Pharmaceuticals, Inc.$185.6M59
UPBUpstream Bio, Inc.$186.8M26
CGENCompugen Ltd.$187.2M78
YARWYarrow Bioscience, Inc.$187.8M60
RNACCartesian Therapeutics, Inc.$190.2M24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atrium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNA news & analysis

Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

PRNewsWire · 27 Oct 2026positive

Atrium Therapeutics announced that the first participant has been dosed in Corventis, a Phase 1/2 trial evaluating ATR 1072 for PRKAG2 syndrome. The company expects initial proof-of-concept data in the second half of 2027.

Why it matters — The trial marks the start of clinical evaluation for Atrium’s lead investigational therapy in PRKAG2 syndrome, with initial data expected in 2027.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 20 Oct 2026neutral

Atrium Therapeutics granted a newly hired non-executive employee inducement awards on October 20, 2026: options for 9,500 shares at an exercise price of $7.98 and restricted stock units for 4,750 shares. Vesting is contingent on continued service and follows the schedules described in the announcement.

Why it matters — The grants provide details about equity-based compensation awarded to a new employee under Atrium’s 2026 Employment Inducement Incentive Award Plan.

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

PRNewsWire · 20 Oct 2026negative

Yakira Capital Management, an Atrium Therapeutics shareholder, urged the board to launch a strategic review, curb cash spending and explain its decision to issue $50 million in equity. Yakira cited a roughly 44% share decline and said the financing was at a valuation near half of net cash.

Why it matters — The appeal raises questions about Atrium’s cash use, financing decision and potential strategic alternatives.

Atrium Therapeutics Announces $50 Million Private Placement

PRNewsWire · 8 Oct 2026positive

Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a private placement expected to generate approximately $50 million in gross proceeds, before fees and other offering expenses.

Why it matters — The financing would provide Atrium with capital from the private placement, a development relevant to investors tracking the company.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 21 Sept 2026neutral

Atrium Therapeutics announced it awarded inducement grants on September 20, 2026 under its 2026 Employment Inducement Incentive Award Plan as a material inducement to the employment of one newly hired non-executive individual.

Why it matters — The grant indicates Atrium is hiring new personnel, a routine corporate action that may signal modest team expansion but carries no direct business impact.

FAQ

Frequently asked questions about RNA stock

What is the RNA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Atrium Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNA stock a buy right now?

Of the 5 analysts covering Atrium Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atrium Therapeutics, Inc. 5 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNA?

As at 31 Oct 2026, Atrium Therapeutics, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (74 of 100).

Will RNA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +202.3% from the last close, and Ticker Nerd's factor model ranks Atrium Therapeutics, Inc. 5 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNA stock forecast for 2030?

No analyst covering Atrium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.

What does Atrium Therapeutics, Inc. do?

Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease.

What is the latest news on RNA?

The most recent item we track (PRNewsWire, 27 Oct 2026): "Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome". Atrium Therapeutics announced that the first participant has been dosed in Corventis, a Phase 1/2 trial evaluating ATR 1072 for PRKAG2 syndrome. The company expects initial proof-of-concept data in the second half of 2027.

Company

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision. Its current pipeline centers on rare genetic cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Atrium Therapeutics also advances research programs aimed at additional rare cardiac conditions, reflecting its focus on genetically defined diseases with significant unmet medical need. Based in San Diego, California, Atrium Therapeutics operates as a specialist developer in the broader biotechnology sector, with a business model centered on translating RNA science into potential treatments for inherited heart disorders.

CEO Ms. Kathleen P. Gallagher · 511 employees · United States · https://atriumtherapeutics.com